A fundamental analysis of Procter & Gamble Health (PGHL) covering revenue trends, profitability, valuation, and shareholding patterns.
Procter & Gamble Health Revenue Trend
In FY2025, Procter & Gamble Health's revenue contracted 19.1% to ₹945 Cr from ₹1,167 Cr.
On a 11-year view, revenue grew from ₹867 Cr to ₹945 Cr at a 0.8% CAGR — slow growth that may signal a maturing business.
Procter & Gamble Health's ₹945 Cr revenue base puts it in the smaller bracket among pharmaceuticals companies in India.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹945 Cr | -19.1% |
| FY2024 | ₹1,167 Cr | -6.5% |
| FY2023 | ₹1,248 Cr | +10.7% |
| FY2022 | ₹1,128 Cr | +9.8% |
| FY2021 | ₹1,027 Cr | — |
View Procter & Gamble Health's full 10-year revenue trend with CAGR analysis →
Procter & Gamble Health Profitability
Procter & Gamble Health delivered net profit of ₹234 Cr in FY2025, a solid 16.6% jump from ₹201 Cr in FY2024.
A stronger net margin of 24.8% in FY2025 (from 17.2%) points to better profitability per rupee of revenue.
Per-share earnings moved to ₹141.22 in FY2025 from ₹121.07 in FY2024.
Is Procter & Gamble Health Undervalued
Procter & Gamble Health shares are currently trading at ₹6,501.50.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Procter & Gamble Health Shareholding Pattern
Promoters haven't moved — their 51.8% holding has been unchanged for 4 quarters.
The FII stake is at 6.3% as of June 2026, compared to 7.2% in the year-ago period.
On the domestic institutional side, the holding is 12.4% as of June 2026 — down from 13.9%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 51.8% | 6.3% | 12.4% | 29.4% |
| Mar 2026 | 51.8% | 6.2% | 13.7% | 28.3% |
| Dec 2025 | 51.8% | 7.0% | 13.8% | 27.4% |
| Sep 2025 | 51.8% | 7.2% | 13.9% | 27.0% |
Track quarterly shareholding changes for Procter & Gamble Health →
Procter & Gamble Health Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹7.94B (down 0.0% YoY from ₹7.94B).
Top categories: Other Assets (29.8%), Cash & ST Investments (22.9%), Receivables (18.3%).
Of the ₹7.94B in liabilities and equity, 67.6% is shareholder equity, 1.0% is interest-bearing debt, and 31.4% is operating liabilities. Over the year, debt is down 20.3% and equity is down 0.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 1.82B |
| Receivables | 1.45B |
| Inventories | 1.09B |
| Property, Plant & Equipment | 1.16B |
| Investments | 43.70M |
| Intangibles & Goodwill | 7.10M |
| Other Assets | 2.37B |
| Category | Value |
|---|---|
| Equity | 5.37B |
| Short-term Debt | 28.10M |
| Long-term Debt | 48.10M |
| Trade Payables | 1.72B |
| Other Liabilities | 780.20M |
Procter & Gamble Health Key Highlights
In summary, Procter & Gamble Health (PGHL) presents the following picture for fundamental analysts.
Revenue of ₹945 Cr in FY2025, down 19.1% year-over-year.
Long-term revenue has been compounding at 0.8% annually over 11 years.
The company is profitable, with a net margin of 24.8% and net income of ₹234 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Procter & Gamble Health.